Azole antifungal ketoconazole (KET) was demonstrated to activate aryl hydrocarbon receptor (AhR). Since clinically used KET is a racemic mixture of two cis-enantiomers (2R,4S)-(+)-KET and (2S,4R)-(-)-KET, we examined the effects of KET enantiomers on AhR signaling pathway. (+)-KET dose-dependently activated AhR in human gene reporter cell line AZ-AHR, and displayed 5-20× higher agonist activity (efficacy), as compared to (-)-KET; both enantiomers were AhR antagonists with equal potency (IC50). Consistently, (+)-KET strongly induced CYP1A1 mRNA and protein in human HepG2 cells, while (-)-KET exerted less than 10% of (+)-KET activity. In primary human hepatocytes, both enantiomers preferentially induced CYP1A2 over CYP1A1 mRNA and protein, and the potency of (+)-KET was slightly higher as compared to (-)-KET. Ligand binding assay with guinea pig liver cytosols revealed that both (+)-KET and (-)-KET are weak ligands of AhR that displaced [3H]-TCDD with comparable potency. Similarly, both enantiomers weakly transformed AhR to DNA-binding form with similar potency, as showed by EMSA, in guinea pig liver cytosolic extracts and nuclear extracts from mouse Hepa-1 cells. We also examined effects of KET on glucocorticoid receptor (GR), a regulator of AhR activity. Both KET enantiomers antagonized GR with similar potency, as revealed by gene reporter assay in AZ-GR cell line and down-regulation of tyrosine aminotransferase mRNA in human hepatocytes. Finally, we demonstrate enantiospecific antifungal activities of KET enantiomers in six Candida spp. strains. In conclusion, the significance of current study is providing the first evidence of enatiospecific effects of cis-enantiomers of ketoconazole on AhR-CYP1A pathway.

Department of Environmental Toxicology University of California Davis Davis California United States of America

Department of Microbiology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Regional Centre of Advanced Technologies and Materials Faculty of Science Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D (1991) Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 35: 347–352. PubMed

Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, et al. (1984) High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 144: 2150–2153. PubMed

Stricker BH, Blok AP, Bronkhorst FB, Van Parys GE, Desmet VJ (1986) Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J Hepatol 3: 399–406. PubMed

Bercoff E, Bernuau J, Degott C, Kalis B, Lemaire A, et al. (1985) Ketoconazole-induced fulminant hepatitis. Gut 26: 636–638. PubMed PMC

Benson GD, Anderson PK, Combes B, Ishak KG (1988) Prolonged jaundice following ketoconazole-induced hepatic injury. Dig Dis Sci 33: 240–246. PubMed

Daneshmend TK, Warnock DW (1988) Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 14: 13–34. PubMed

Rotstein DM, Kertesz DJ, Walker KA, Swinney DC (1992) Stereoisomers of ketoconazole: preparation and biological activity. J Med Chem 35: 2818–2825. PubMed

Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J (2004) Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality 16: 79–85. PubMed

Allqvist A, Miura J, Bertilsson L, Mirghani RA (2007) Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol 63: 173–179. PubMed

Boxenbaum H (1999) Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 2: 47–52. PubMed

Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, et al. (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28: 1440–1448. PubMed

Duret C, Daujat-Chavanieu M, Pascussi JM, Pichard-Garcia L, Balaguer P, et al. (2006) Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 70: 329–339. PubMed

Dvorak Z (2011) Drug-drug interactions by azole antifungals: Beyond a dogma of CYP3A4 enzyme activity inhibition. Toxicol Lett 202: 129–132. PubMed

Korashy HM, Shayeganpour A, Brocks DR, El-Kadi AO (2007) Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol Sci 97: 32–43. PubMed

Jack SM, Dobbins M, Sword W, Novotna G, Brooks S, et al. (2011) Evidence-informed decision-making by professionals working in addiction agencies serving women: a descriptive qualitative study. Subst Abuse Treat Prev Policy 6: 29. PubMed PMC

Vrzal R, Daujat-Chavanieu M, Pascussi JM, Ulrichova J, Maurel P, et al. (2008) Microtubules-interfering agents restrict aryl hydrocarbon receptor-mediated CYP1A2 induction in primary cultures of human hepatocytes via c-jun-N-terminal kinase and glucocorticoid receptor. Eur J Pharmacol 581: 244–254. PubMed

Novotna A, Pavek P, Dvorak Z (2011) Novel stably transfected gene reporter human hepatoma cell line for assessment of aryl hydrocarbon receptor transcriptional activity: construction and characterization. Environ Sci Technol 45: 10133–10139. PubMed

Novotna A, Pavek P, Dvorak Z (2012) Construction and characterization of a reporter gene cell line for assessment of human glucocorticoid receptor activation. Eur J Pharm Sci 47: 842–847. PubMed

Denison MS, Rogers JM, Rushing SR, Jones CL, Tetangco SC, et al. (2002) Analysis of the aryl hydrocarbon receptor (AhR) signal transduction pathway. Curr Protoc Toxicol Chapter 4: Unit4 8. PubMed

Castro-Puyana M, Garcia-Ruiz C, Cifuentes A, Crego AL, Marina ML (2006) Identification and quantitation of cis-ketoconazole impurity by capillary zone electrophoresis-mass spectrometry. J Chromatogr A 1114: 170–177. PubMed

Monostory K, Dvorak Z (2011) Steroid regulation of drug-metabolizing cytochromes P450. Curr Drug Metab 12: 154–172. PubMed

Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, et al. (2008) Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos 36: 339–348. PubMed

Hasselberg L, Grosvik BE, Goksoyr A, Celander MC (2005) Interactions between xenoestrogens and ketoconazole on hepatic CYP1A and CYP3A, in juvenile Atlantic cod (Gadus morhua). Comp Hepatol 4: 2. PubMed PMC

Babin M, Casado S, Chana A, Herradon B, Segner H, et al. (2005) Cytochrome P4501A induction caused by the imidazole derivative Prochloraz in a rainbow trout cell line. Toxicol In Vitro 19: 899–902. PubMed

Sun G, Thai SF, Tully DB, Lambert GR, Goetz AK, et al. (2005) Propiconazole-induced cytochrome P450 gene expression and enzymatic activities in rat and mouse liver. Toxicol Lett 155: 277–287. PubMed

Schwartz SL, Rendell M, Ahmann AJ, Thomas A, Arauz-Pacheco CJ, et al. (2008) Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. Clin Ther 30: 1081–1088. PubMed

Arakaki R, Welles B (2010) Ketoconazole enantiomer for the treatment of diabetes mellitus. Expert Opin Investig Drugs 19: 185–194. PubMed

Pivotal role of the aryl hydrocarbon receptor in modulations caused by benzo[a]pyrene and ketoconazole in the estrogenic responses induced by 17β-estradiol in male goldfish

Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes

Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 Cells